Company Description
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products.
It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.
The company’s lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications.
The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024.
PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
| Country | United States |
| Founded | 2020 |
| IPO Date | Nov 21, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Graydon Bensler |
Contact Details
Address: 120 Newport Center Drive, Suite 249 Newport Beach, California 92660 United States | |
| Phone | 866 445 4886 |
| Website | pmgcholdings.com |
Stock Details
| Ticker Symbol | ELAB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 1840563 |
| CUSIP Number | 73017P508 |
| ISIN Number | US73017P5089 |
| Employer ID | 85-1399981 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Graydon Bensler C.F.A. | Chief Executive Officer, Chief Financial Officer, Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | DEF 14A | Other definitive proxy statements |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| May 4, 2026 | PRE 14A | Other preliminary proxy statements |
| May 4, 2026 | DEF 14C | Filing |
| Apr 28, 2026 | 8-K | Current Report |
| Apr 27, 2026 | DEF 14C | Filing |
| Apr 24, 2026 | PRE 14C | Filing |
| Apr 23, 2026 | 8-K | Current Report |
| Apr 21, 2026 | 8-K | Current Report |